A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZEDSTUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS.CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVEMETASTATIC BREAST CANCER
A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZEDSTUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS.CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVEMETASTATIC BREAST CANCER
A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evaluate the anti-tumor activity of the combination therapyEstudio de prueba de concepto en fase II, aleatorizado, abierto de WX-671 en combinación con gemcitabina frente a gemcitabina sola en pacientes con cáncer de páncreas localmente avanzado no resecable cuyo objetivo es evaluar la actividad antitumoral de la terapia en combinación
100 Clinical Results associated with Wilex AG
0 Patents (Medical) associated with Wilex AG
100 Deals associated with Wilex AG
100 Translational Medicine associated with Wilex AG